上海医药(02607)拟公开挂牌转让中美施贵宝 30%股权

Core Viewpoint - Shanghai Pharmaceuticals (02607) plans to optimize its investment structure and maximize asset value by publicly transferring its 30% stake in Celgene Corporation through a property trading agency, with a minimum listing price of approximately RMB 1.023 billion [1] Group 1 - The company intends to transfer its 30% equity stake in Celgene Corporation [1] - The transfer will be conducted via a public listing process [1] - The minimum listing price is set at approximately RMB 1.023 billion, subject to relevant state evaluation management procedures [1]